论文部分内容阅读
目的比较多西他赛和吉西他滨不同时间点给药的疗效及不良反应。方法病理诊断的210例Ⅲ、Ⅳ期非小细胞肺癌(NSCLC)患者随机均分为六组,分别于第1、8天的8:00(D1组)、14:00(D2组)和20:00(D3组)给予多西他赛40mg/m2静脉滴注;G1、G2、G3组分别于上述时间点给予吉西他滨1g/m2静脉滴注。所有病例均于第2、23天给予顺铂75mg/m2静脉滴注。化疗2个周期后评价各组疗效和不良反应。结果 D1、D2、D3组之间,G1、G2、G3组之间的疗效和不良反应均无统计学差异。D1组与G1组、D2组与G2组之间的的疗效和不良反应亦无统计学差异;G3组有效率高于D3组(56.3%vs.33.3%)(P<0.05)。结论在20:00给药,吉西他滨的疗效优于多西他赛。
Objective To compare the efficacy and side effects of docetaxel and gemcitabine at different time points. Methods Totally 210 patients with stage Ⅲ and Ⅳ non-small cell lung cancer (NSCLC) diagnosed by pathology were divided into six groups randomly at 8:00 (D1 group), 14:00 (D2 group) and 20 (Group D3) was given docetaxel 40mg / m2 intravenously; G1, G2, G3 group were given gemcitabine 1g / m2 intravenous infusion at the above time points. All cases were given intravenous infusion of cisplatin 75mg / m2 on the 2nd and 23rd days. After 2 cycles of chemotherapy, the curative effect and adverse reactions in each group were evaluated. Results There was no significant difference in the efficacy and adverse reactions between D1, D2 and D3 groups, G1, G2 and G3 groups. The efficacy and adverse reactions between D1 and G1, D2 and G2 were also not statistically different. The effective rate of G3 was higher than that of D3 (56.3% vs.33.3%) (P <0.05). Conclusions Gemcitabine is superior to docetaxel at 20:00.